Results 51 to 60 of about 17,677 (210)
Prognostic role of TAPSE to PASP ratio in outpatients with left ventricular systolic dysfunction
ESC Heart Failure, Volume 12, Issue 2, Page 912-922, April 2025.Abstract Aims Few data are available regarding the role of tricuspid annulus plane systolic excursion to pulmonary artery systolic pressure (TAPSE/PASP), a measurement of right ventricular to pulmonary artery coupling, in patients with chronic heart failure and left ventricular systolic dysfunction.
Mauro Riccardi +9 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1346-1357, April 2025.Abstract Aims Iron deficiency (ID) is prevalent in chronic heart failure (HF) but lacks a consensus definition. This study evaluates the prevalence and the prognostic impact of ID using different criteria on all‐cause and cardiovascular mortality, as well as first hospitalization for HF in patients with new‐onset chronic HF.
Abdullahi Ahmed Mohamed +12 more
wiley +1 more source
FDG PET/CT imaging and circulating biomarkers of inflammation in desmoplakin cardiomyopathy
ESC Heart Failure, Volume 12, Issue 2, Page 1485-1489, April 2025.Abstract Aims Inflammation has been implicated in the pathogenesis of desmoplakin (DSP) cardiomyopathy, and retrospective studies have described abnormal myocardial fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) findings in symptomatic patients eventually diagnosed with DSP cardiomyopathy.
Sanjay Divakaran +10 more
wiley +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018 Background In acute decompensated heart failure, guidelines recommend increasing loop diuretic dose or adding a thiazide diuretic when diuresis is inadequate.
Meredith A. Brisco‐Bacik +7 more
doaj +1 more source
Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial
ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad +9 more
wiley +1 more source
Combination diuretic therapies in heart failure: Insights from GUIDE-IT
American Heart Journal PlusIntroduction: Diuretics are the mainstay of maintaining and restoring euvolemia in the management of heart failure. Loop diuretics are often preferred, however, combination diuretic therapy (CDT) with a thiazide diuretic is often used to overcome ...
Jeffery Budweg +8 more
doaj +1 more source
Use of glucagon‐like peptide‐1 receptor agonists in patients with left ventricular assist devices
ESC Heart Failure, EarlyView.Key question: does GLP1‐RA therapy improve heart transplantation rates and clinical outcomes in patients with LVADs? Key findings: in this propensity score‐matched cohort study of 1068 LVAD recipients, GLP1‐RA use was associated with higher heart transplantation rates (18.9% vs.
Ramzi Ibrahim +12 more
wiley +1 more source
Combination of thiazide and loop diuretics for the treatment of acute heart failure
Cardiologia HungaricaAcute heart failure (AHF) is a serious condition with a high mortality rate. It is considered as the most common cause of unplanned hospitalizations in the elderly population. In 90% of all cases AHF presents with congestive symptoms, thus mostly treated
Krisztina Fekete +2 more
doaj +1 more source
ESC Heart Failure, EarlyView.This state‐of‐the‐art review outlines a practical, evidence‐based framework for early acute heart failure management to address critical gaps in current guidance and improve early treatment outcomes. Key components include early identification of co‐existing conditions, bedside haemodynamic profiling, a structured diagnostic approach incorporating both
Anika S. Naidu +22 more
wiley +1 more source
ESC Heart Failure, EarlyView.Impact of empagliflozin in patients with and without T2D or CKD in the EMPACT‐MI trial. Baseline characteristics, HF outcomes and subgroup analysis of efficacy endpoints are shown. # Hazard ratios estimated via Cox proportional hazard model (unless indicated otherwise). ^ Rate ratios via negative binomial regression.
Francesco Fioretti +23 more
wiley +1 more source